Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5VSL9
UPID:
STRP1_HUMAN
Alternative names:
Protein FAM40A
Alternative UPACC:
Q5VSL9; Q0V925; Q5VSL8; Q658K2; Q6ZV31; Q8N598; Q96SN2; Q9C0A2
Background:
Striatin-interacting protein 1, also known as Protein FAM40A, is pivotal in cell morphology and cytoskeletal organization. It is essential for cortical actin filament dynamics and maintaining cell shape.
Therapeutic significance:
Understanding the role of Striatin-interacting protein 1 could open doors to potential therapeutic strategies.